相关实验视频

Updated: Jun 22, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

一种对脂质敏感的蜘蛛毒素通过多模式机制表现出选择性抗白血病疗效

Peng Zhang^1,2,3, Wu Luo^1,4, Zixin Zhang^1,2,3

¹The National & Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, Hunan, 410081, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|July 4, 2024

概括

抗癌素Lycosin-I通过向癌细胞膜并诱导多个细胞死亡途径,有效治疗白血病. 这种可以作为一种强效和特定的抗白血病药物候选剂,具有最小的副作用.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

抗癌 (ACP) 提供潜在的癌症治疗方法,但它们的机制需要进一步研究以改善治疗应用.
莱科辛-I是一种来自Lycosa singorensis毒素的,具有显著的抗癌特性,并自组装成纳米球.

研究的目的:

阐明Lycosin-I在治疗白血病中的多模式作用机制.
评估Lycosin-I对K562白血病细胞的治疗潜力和特异性.

主要方法:

研究了Lycosin-I与K562细胞膜的相互作用,包括脂质结合和膜溶解.
通过PI3K-AKT-mTOR途径分析了Lycosin-I对细胞亡,细胞循环停止,铁亡和自的作用.
在K562异种移植小鼠模型中评估了Lycosin-I的体内疗效和安全性.

主要成果:

莱科辛-I选择性地与K562细胞膜结合,在高度下诱导快速的膜溶解.
在低度下,Lycosin-I会触发亡,G1细胞周期停止和铁亡,同时通过调节PI3K-AKT-mTOR通路来激活自.
在小鼠体内给予Lycosin-I有效抑制K562瘤生长,没有可观察到的副作用.

结论:

莱科辛-I对白血病表现出多模式的作用机制,涉及直接破坏膜和诱导多个细胞死亡途径.
莱科辛-I表现出高强度和特异性,将其定位为开发新型抗白血病治疗药物的有希望的化合物.

关键词:

在 PI3K-AKT-mTOR 信号通路中.抗癌是一种抗癌.灭症 (apoptosis) 是一种死亡的过程.细胞循环停止细胞循环停止铁性化 (ferroptosis) 是一种这种白血病是白血病.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...